NRIX
Nurix Therapeutics·NASDAQ
--
--(--)
--
--(--)
NRIX fundamentals
During Q4 2025, Nurix Therapeutics (NRIX) reported revenue of 13.58M, a YoY change of 2.21%. Net income was -78.22M, a YoY change of -33.60%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jun 1, 2019 | Sep 1, 2019 | Dec 1, 2019 | Mar 1, 2020 | Jun 1, 2020 | Sep 1, 2020 | Dec 1, 2020 | Mar 1, 2021 | Jun 1, 2021 | Sep 1, 2021 | Dec 1, 2021 | Mar 1, 2022 | Jun 1, 2022 | Sep 1, 2022 | Dec 1, 2022 | Mar 1, 2023 | Jun 1, 2023 | Sep 1, 2023 | Dec 1, 2023 | Mar 1, 2024 | Jun 1, 2024 | Sep 1, 2024 | Dec 1, 2024 | Mar 1, 2025 | Jun 1, 2025 | Sep 1, 2025 | -- |
End Date | Aug 31, 2019 | Nov 30, 2019 | Feb 29, 2020 | May 31, 2020 | Aug 31, 2020 | Nov 30, 2020 | Feb 28, 2021 | May 31, 2021 | Aug 31, 2021 | Nov 30, 2021 | Feb 28, 2022 | May 31, 2022 | Aug 31, 2022 | Nov 30, 2022 | Feb 28, 2023 | May 31, 2023 | Aug 31, 2023 | Nov 30, 2023 | Feb 29, 2024 | May 31, 2024 | Aug 31, 2024 | Nov 30, 2024 | Feb 28, 2025 | May 31, 2025 | Aug 31, 2025 | Nov 30, 2025 | -- |
Fiscal Year-End | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | -- |
Revenue | 10.58M -- | 1.86M -- | 2.86M -- | 4.18M -- | 4.08M -61.39% | 6.69M +259.24% | 5.01M +74.97% | 7.09M +69.56% | 10.25M +150.97% | 7.40M +10.57% | 9.62M +92.00% | 11.43M +61.22% | 10.79M +5.26% | 6.78M -8.29% | 12.69M +31.85% | 30.68M +168.33% | 18.47M +71.13% | 15.16M +123.49% | 16.59M +30.74% | 12.09M -60.58% | 12.59M -31.84% | 13.28M -12.37% | 18.45M +11.26% | 44.06M +264.34% | 7.89M -37.29% | 13.58M +2.21% | 83.98M -- |
Sales and Services Revenue | 10.58M -- | 1.86M -- | 2.86M -- | 4.18M -- | 4.08M -61.39% | 6.69M +259.24% | 5.01M +74.97% | 7.09M +69.56% | 10.25M +150.97% | 7.40M +10.57% | 9.62M +92.00% | 11.43M +61.22% | 10.79M +5.26% | 6.78M -8.29% | 12.69M +31.85% | 30.68M +168.33% | 18.47M +71.13% | 15.16M +123.49% | 16.59M +30.74% | 12.09M -60.58% | 12.59M -31.84% | 13.28M -12.37% | 18.45M +11.26% | 44.06M +264.34% | 7.89M -37.29% | 13.58M +2.21% | 83.98M -- |
Cost of Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | 10.58M -- | 1.86M -- | 2.86M -- | 4.18M -- | 4.08M -61.39% | 6.69M +259.24% | 5.01M +74.97% | 7.09M +69.56% | 10.25M +150.97% | -22.35M -434.19% | 9.62M +92.00% | 11.43M +61.22% | 10.79M +5.26% | -31.84M -42.45% | 12.69M +31.85% | 30.68M +168.33% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 13.19M -- | 15.43M -- | 15.42M -- | 17.41M -- | 23.28M +76.45% | 26.70M +73.06% | 29.53M +91.56% | 33.51M +92.42% | 39.25M +68.62% | 45.35M +69.87% | 52.37M +77.31% | 57.15M +70.56% | 57.51M +46.52% | 55.47M +22.32% | 55.64M +6.25% | 57.44M +0.51% | 58.48M +1.69% | 60.49M +9.05% | 61.80M +11.08% | 60.63M +5.56% | 67.20M +14.91% | 77.94M +28.84% | 81.32M +31.57% | 92.38M +52.36% | 99.28M +47.74% | 96.67M +24.03% | 369.65M -- |
Selling, General and Administrative Expenses | 2.18M -- | 2.60M -- | 2.45M -- | 3.27M -- | 4.34M +98.63% | 6.25M +140.28% | 6.53M +166.53% | 7.51M +129.69% | 8.34M +92.32% | 8.82M +41.04% | 9.23M +41.32% | 9.65M +28.53% | 9.75M +16.84% | 9.37M +6.23% | 9.82M +6.43% | 11.68M +20.97% | 10.62M +8.98% | 10.78M +15.08% | 11.80M +20.14% | 11.71M +0.27% | 11.72M +10.31% | 10.72M -0.58% | 11.65M -1.23% | 14.28M +21.96% | 13.16M +12.30% | 13.65M +27.35% | 52.74M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 31.20M -- | -- -- | -- -- | -- -- | 38.00M +21.78% | -- -- | -- -- | 10.62M -- | 10.78M -71.63% | 11.80M -- | 11.71M -- | 11.72M +10.31% | 10.72M -0.58% | 11.65M -1.23% | 14.28M +21.96% | 13.16M +12.30% | 13.65M +27.35% | 52.74M -- |
Research and Development Expenses | 11.01M -- | 12.82M -- | 12.97M -- | 14.14M -- | 18.94M +72.05% | 20.45M +59.43% | 23.00M +77.40% | 25.99M +83.81% | 30.91M +63.19% | 36.53M +78.68% | 43.14M +87.53% | 47.49M +82.71% | 47.76M +54.54% | 46.11M +26.21% | 45.82M +6.21% | 45.76M -3.64% | 47.86M +0.20% | 49.71M +7.82% | 50.01M +9.14% | 48.92M +6.90% | 55.48M +15.93% | 67.22M +35.22% | 69.66M +39.31% | 78.10M +59.63% | 86.12M +55.22% | 83.02M +23.50% | 316.90M -- |
Operating Income | -2.61M -- | -13.56M -- | -12.55M -- | -13.23M -- | -19.19M -634.76% | -20.01M -47.51% | -24.52M -95.35% | -26.41M -99.65% | -29.00M -51.09% | -37.95M -89.69% | -42.74M -74.31% | -45.72M -73.07% | -46.72M -61.11% | -48.69M -28.29% | -42.95M -0.49% | -26.77M +41.45% | -40.01M +14.35% | -45.33M +6.89% | -45.22M -5.28% | -48.54M -81.36% | -54.61M -36.49% | -64.66M -42.62% | -62.86M -39.02% | -48.32M +0.45% | -91.39M -67.34% | -83.09M -28.52% | -285.67M -- |
Non-Operating Income (Loss) | 195.00K -- | 255.00K -- | 173.00K -- | 223.00K -- | 675.00K +246.15% | 135.00K -47.06% | 318.00K +83.82% | 171.00K -23.32% | 39.00K -94.22% | 295.00K +118.52% | 211.00K -33.65% | 314.00K +83.63% | 1.01M +2487.18% | 1.97M +568.81% | 2.22M +951.66% | 2.49M +692.36% | 3.03M +200.30% | 3.38M +71.21% | 3.79M +70.84% | 4.08M +64.15% | 5.74M +89.34% | 6.12M +81.05% | 6.51M +71.80% | 5.62M +37.56% | 4.96M -13.47% | 4.87M -20.31% | 21.97M -- |
Other Non-Operating Income (Loss) | 195.00K -- | 255.00K -- | 173.00K -- | 223.00K -- | 675.00K +246.15% | 135.00K -47.06% | 318.00K +83.82% | 171.00K -23.32% | 39.00K -94.22% | -528.00K -491.11% | 211.00K -33.65% | 314.00K +83.63% | 1.01M +2487.18% | -1.53M -190.53% | 2.22M +951.66% | 2.49M +692.36% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -823.00K -- | -- -- | -- -- | -- -- | -3.51M -326.12% | -- -- | -- -- | -3.03M -- | -3.38M +3.68% | -3.79M -- | -4.08M -- | -5.74M -89.34% | -6.12M -81.05% | -6.51M -71.80% | -5.62M -37.56% | -4.96M +13.47% | -4.87M +20.31% | -21.97M -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 823.00K -- | -- -- | -- -- | -- -- | 3.51M +326.12% | -- -- | -- -- | 3.03M -- | 3.38M -3.68% | 3.79M -- | 4.08M -- | 5.74M +89.34% | 6.12M +81.05% | 6.51M +71.80% | 5.62M +37.56% | 4.96M -13.47% | 4.87M -20.31% | 21.97M -- |
Pretax Income From Continuing Operations | -2.42M -- | -13.31M -- | -12.38M -- | -13.01M -- | -18.52M -666.12% | -19.87M -49.32% | -24.20M -95.51% | -26.24M -101.76% | -28.96M -56.39% | -37.66M -89.49% | -42.53M -75.73% | -45.40M -73.00% | -45.71M -57.85% | -46.72M -24.06% | -40.73M +4.23% | -24.28M +46.53% | -36.98M +19.09% | -41.96M +10.19% | -41.43M -1.71% | -44.46M -83.12% | -48.87M -32.16% | -58.54M -39.53% | -56.35M -36.02% | -42.70M +3.94% | -86.42M -76.82% | -78.22M -33.62% | -263.70M -- |
Income Tax Expense | 10.00K -- | 210.00K -- | 11.00K -- | -20.59M -- | 0 -100.00% | 41.00K -80.48% | 71.00K +545.45% | 139.00K +100.68% | -123.00K -- | 44.00K +7.32% | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 90.00K -- | 90.00K -- | 82.00K -- | 8.00K -- | -- -- | 760.00K +744.44% | 0 -100.00% | -- -- | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 131.00K -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 270.00K -- | -- -- | -- -- | -- -- | 760.00K +181.48% | -- -- |
Net Income | -2.43M -- | -13.52M -- | -12.39M -- | 7.58M -- | -18.52M -662.96% | -19.91M -47.30% | -24.27M -95.91% | -26.38M -448.05% | -28.84M -55.72% | -37.70M -89.32% | -42.53M -75.21% | -45.40M -72.09% | -45.71M -58.52% | -46.72M -23.91% | -40.73M +4.23% | -24.28M +46.53% | -36.98M +19.09% | -41.96M +10.19% | -41.52M -1.93% | -44.55M -83.49% | -48.96M -32.38% | -58.55M -39.55% | -56.35M -35.73% | -43.46M +2.43% | -86.42M -76.53% | -78.22M -33.60% | -264.46M -- |
Net Income Attributable to Owners of the Company | -2.43M -- | -13.52M -- | -12.39M -- | 7.58M -- | -18.52M -662.96% | -19.91M -47.30% | -24.27M -95.91% | -26.38M -448.05% | -28.84M -55.72% | -37.70M -89.32% | -42.53M -75.21% | -45.40M -72.09% | -45.71M -58.52% | -46.72M -23.91% | -40.73M +4.23% | -24.28M +46.53% | -36.98M +19.09% | -41.96M +10.19% | -41.52M -1.93% | -44.55M -83.49% | -48.96M -32.38% | -58.55M -39.55% | -56.35M -35.73% | -43.46M +2.43% | -86.42M -76.53% | -78.22M -33.60% | -264.46M -- |
Net Income Attributable to Common Stockholders | -2.43M -- | -13.52M -- | -12.39M -- | 7.58M -- | -18.52M -662.96% | -19.91M -47.30% | -24.27M -95.91% | -26.38M -448.05% | -28.84M -55.72% | -37.70M -89.32% | -42.53M -75.21% | -45.40M -72.09% | -45.71M -58.52% | -46.72M -23.91% | -40.73M +4.23% | -24.28M +46.53% | -36.98M +19.09% | -41.96M +10.19% | -41.52M -1.93% | -44.55M -83.49% | -48.96M -32.38% | -58.55M -39.55% | -56.35M -35.73% | -43.46M +2.43% | -86.42M -76.53% | -78.22M -33.60% | -264.46M -- |
Other Comprehensive Income | -1.00K -- | -2.00K -- | 59.00K -- | 82.00K -- | -1.00K -- | -51.00K -2450.00% | -38.00K -164.41% | -19.00K -123.17% | -89.00K -8800.00% | -549.00K -976.47% | -1.46M -3736.84% | -1.02M -5263.16% | -657.00K -638.20% | -577.00K -5.10% | 1.07M +173.53% | 1.34M +231.89% | 675.00K +202.74% | 573.00K +199.31% | 305.00K -71.55% | 215.00K -84.00% | 479.00K -29.04% | -194.00K -133.86% | 76.00K -75.08% | -246.00K -214.42% | 139.00K -70.98% | -14.00K +92.78% | -45.00K -- |
Total Comprehensive Income | -2.43M -- | -13.52M -- | -12.33M -- | 7.66M -- | -18.52M -662.69% | -19.96M -47.66% | -24.31M -97.15% | -26.40M -444.57% | -28.92M -56.19% | -38.25M -91.59% | -43.99M -80.94% | -46.42M -75.83% | -46.37M -60.30% | -47.29M -23.64% | -39.66M +9.84% | -22.93M +50.60% | -36.31M +21.69% | -41.38M +12.50% | -41.21M -3.91% | -44.33M -93.31% | -48.48M -33.52% | -58.74M -41.95% | -56.27M -36.55% | -43.71M +1.40% | -86.28M -77.99% | -78.23M -33.18% | -264.50M -- |
Total Comprehensive Income Attributable to Owners of the Company | -2.43M -- | -13.52M -- | -12.33M -- | 7.66M -- | -18.52M -662.69% | -19.96M -47.66% | -24.31M -97.15% | -26.40M -444.57% | -28.92M -56.19% | -38.25M -91.59% | -43.99M -80.94% | -46.42M -75.83% | -46.37M -60.30% | -47.29M -23.64% | -39.66M +9.84% | -22.93M +50.60% | -36.31M +21.69% | -41.38M +12.50% | -41.21M -3.91% | -44.33M -93.31% | -48.48M -33.52% | -58.74M -41.95% | -56.27M -36.55% | -43.71M +1.40% | -86.28M -77.99% | -78.23M -33.18% | -264.50M -- |
Basic EPS | -0.66 -- | -- -- | -3.5 -- | 0 -- | -1.09 -65.15% | -0.51 -- | -0.63 +82.00% | -0.6 -- | -0.65 +40.37% | -0.84 -64.71% | -0.95 -50.79% | -1.01 -68.33% | -0.9 -38.46% | -0.99 -17.86% | -0.75 +21.05% | -0.45 +55.45% | -0.68 +24.44% | -0.86 +13.13% | -0.76 -1.33% | -0.71 -57.78% | -0.67 +1.47% | -0.77 +10.47% | -0.67 +11.84% | -0.52 +26.76% | -1.03 -53.73% | -0.77 -- | -2.99 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.68 -- | -- -- | -0.76 -- | -0.71 -- | -0.67 +1.47% | -- -- | -0.67 +11.84% | -0.52 +26.76% | -1.03 -53.73% | -- -- | -- -- |
Diluted EPS | -0.66 -- | -- -- | -3.5 -- | 0 -- | -1.09 -65.15% | -- -- | -0.63 +82.00% | -0.6 -- | -0.65 +40.37% | -- -- | -0.95 -50.79% | -1.01 -68.33% | -0.9 -38.46% | -- -- | -0.75 +21.05% | -0.45 +55.45% | -0.68 +24.44% | -- -- | -0.76 -1.33% | -0.71 -57.78% | -0.67 +1.47% | -- -- | -0.67 +11.84% | -0.52 +26.76% | -1.03 -53.73% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.68 -- | -- -- | -0.76 -- | -0.71 -- | -0.67 +1.47% | -- -- | -0.67 +11.84% | -0.52 +26.76% | -1.03 -53.73% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for Nurix Therapeutics next quarter?What is the revenue and EPS growth rate for Nurix Therapeutics year over year?What is Nurix Therapeutics's gross profit margin?What were the key takeaways from Nurix Therapeutics’s earnings call?What guidance did Nurix Therapeutics's management provide for the next earnings period?What is Nurix Therapeutics's latest dividend and current dividend yield?What does Nurix Therapeutics do and what are its main business segments?What were the key takeaways from Nurix Therapeutics's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
